ESALF News and Press, Eisai Co Ltd From 08/22/22

There is a critical upcoming catalyst for Biogen shareholders, a topline read out of data from the CLARITY-AD trial in Alzheimer’s due in late September. One lesson from the Aduhelm fiasco is that data that clearly shows patients benefit from treatment is required for commercia...

Eisai Co., Ltd. (ESALY) Q1 2023 Earnings Conference Call August 5, 2022 3:00 AM ET Company Participants Tatsuyuki Yasuno - SVP, CFO & Chief IR Officer Ivan Cheung - SVP, Global Alzheimer's Disease Officer, President, Americas Region Chairman & CEO, Eisai Inc....

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2023 Q1 earnings call. For further details see: Eisai Co., Ltd. 2023 Q1 - Results - Earnings Call Presentation

Eisai ( OTCPK:ESALY ) is reorganizing its R&D efforts under the idea of "Deep Human Biology Learning" that will focus on the root cause of diseases and utilize artificial intelligence. The launch of the reorganization is slated for Oct. 1. As part of the rejiggerin...

New research shows that current monoclonal antibody drugs are targeting a late stage in the amyloid hypothesis of Alzheimer’s disease. This is bad news for Biogen/Eisai, Eli Lilly, and Roche, but this opens new thoughts about Alzheimer’s disease. Biogen’s Aduh...

GE Healthcare will become an independent company in the first quarter of 2023. Pharmaceutical diagnostics revenue was $487 million in Q1 2022, up 2.7% QoQ. General Electric Healthcare has one of the largest profit margins in the GE structure. GE is expanding its business by ac...

A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced on Thursday that their experimental drug for the memory robbing disease did not meet key goals in a mid-stage trial. Developed by the fellow Swiss biote...

Biogen (NASDAQ:BIIB) and Canada-based privately held pharmaceutical company Alectos Therapeutics have reached a license and collaboration agreement to develop and commercialize an experimental therapy called AL01811 for Parkinson’s disease (PD), according to a press release on Monday. ...

Clinical-stage pharma company Cassava Sciences (NASDAQ:SAVA) has added more than 15% to reach a two-month high on Tuesday against a recent selloff among biotech stocks and Alzheimer’s drug developers in particular. More than 5.0M Cassava (SAVA) shares have changed hands compared to the...

Eisai Co., Ltd. (ESALF) Q4 2022 Earnings Conference Call May 13, 2022 3:30 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - Senior VP & President of Neurology Business Group Teruyuki Masaka - VP & Chief Planning Officer Takashi Owa - Senior VP, President & Chief Discover...